These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10211353)

  • 1. The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice.
    Khong TK; Missouris CG; Murda'h M; MacGregor GA
    Postgrad Med J; 1998 Oct; 74(876):600-1. PubMed ID: 10211353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
    Muhlestein JB
    Drugs Aging; 2004; 21(9):583-95. PubMed ID: 15260513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who should receive HMG CoA reductase inhibitors?
    Teo KK; Burton JR
    Drugs; 2002; 62(12):1707-15. PubMed ID: 12149041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of statins in acute coronary syndromes.
    Spin JM; Vagelos RH; ;
    Curr Cardiol Rep; 2002 Jul; 4(4):289-97. PubMed ID: 12052268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population.
    Nilsson G; Samuelsson E; Söderström L; Mooe T
    BMC Fam Pract; 2016 Aug; 17(1):110. PubMed ID: 27515746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    Lopez LM
    Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and the response to myocardial injury.
    Scalia R
    Am J Cardiovasc Drugs; 2005; 5(3):163-70. PubMed ID: 15901204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI).
    Ferrières J; Bataille V; Leclercq F; Geslin P; Ruidavets JB; Grollier G; Bernard P; Cambou JP; Simon T; Danchin N
    Atherosclerosis; 2009 Jun; 204(2):491-6. PubMed ID: 19004441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG CoA reduction in patients with average cholesterol concentrations.
    Braunwald E; Sacks FM; Pfeffer MA; Ridker PM
    Clin Chem; 2011 Jul; 57(7):1072-3. PubMed ID: 21519035
    [No Abstract]   [Full Text] [Related]  

  • 13. Preoperative statin therapy for patients undergoing cardiac surgery.
    Kuhn EW; Slottosch I; Wahlers T; Liakopoulos OJ
    Cochrane Database Syst Rev; 2015 Aug; (8):CD008493. PubMed ID: 26270008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction.
    Jones SP; Lefer DJ
    Acta Physiol Scand; 2001 Sep; 173(1):139-43. PubMed ID: 11678736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of statins and the clinical nursing characteristics in patients with acute myocardial infarction.
    Xie S; Zhou J
    Pak J Pharm Sci; 2017 Sep; 30(5(Special)):1843-1849. PubMed ID: 29084656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
    Foody JM; Rathore SS; Galusha D; Masoudi FA; Havranek EP; Radford MJ; Krumholz HM
    J Am Geriatr Soc; 2006 Mar; 54(3):421-30. PubMed ID: 16551308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials.
    Bavry AA; Mood GR; Kumbhani DJ; Borek PP; Askari AT; Bhatt DL
    Am J Cardiovasc Drugs; 2007; 7(2):135-41. PubMed ID: 17503884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Statin in prevention of periprocedural myonecrosis after percutaneous coronary angioplasty: systematic review and meta-analysis].
    Clergeau MR; Morello R; Lepage O; Hamon M
    Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):181-6. PubMed ID: 18394583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention.
    Veselka J; Procházková S; Duchonová R; Homolová I; Tesar D; Bybee KA
    Heart Vessels; 2006 May; 21(3):146-51. PubMed ID: 16715188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.